News

The approval came earlier than the recently extended PDUFA date of July 24, 2022.

Mustang Bio presented data on MB-106 at the 2022 EHA Congress.

Among treated patients, 42% achieved 5-year event free survival.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Takashi Kei Kishimoto, PhD, and Carsten Brunn, PhD, the chief science and executive officers of Selecta Biosciences, discussed the immunogenicity-mitigating properties of ImmTOR.

Updated date from the B-LIEVE study is expected in the second half of 2022 and first half of 2023.

The trial was placed on hold after elevated liver function test scores.

The director of the Alleghany Health Network Institute of Cellular Therapeutics discussed islet cell transplant for the treatment of chronic pancreatitis.

GC012F also showed efficacy in B-cell non-Hodgkin lymphoma.

Results from the CLIMB THAL-111 and CLIMB SCD-121 trials were presented at the EHA 2022 Congress.

Response rates were significantly higher but patients had more cases of ICANS and CRS with axi-cel treatment compared to tisa-cel treatment.

Participants in the trial achieved a sustained response and experienced low-grade toxicity.

A phase 2 clinical trial evaluating a T-cell memory enriched anti-CD30 CAR-T is now underway.

As of the data cutoff, 3 of 5 treated participants remain in complete response.

Statistically significant differences were seen in global health status, pain, and fatigue.

The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee again voted in favor of the risk-benefit of bluebird bio's gene therapy candidate.

Review top news and interview highlights from the week ending June 10, 2022.

Three of 6 patients have an ongoing response.

The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted in favor of the benefits of bluebird bio's eli-cel in patients with cerebral andrenoleukodystrophy despite substantial safety concerns.

Data from a phase 1/2a study showed notable response rates in patients who had received a median of 5 prior lines of therapy.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The chimeric antigen receptor-modified autologous T cells targeting CLDN18.2 had a manageable safety/tolerability profile and promising efficacy.

100% overall response and complete response rates were seen in patients treated with prior CD19 CAR T-cell therapy.

The fourth and final cohort is dosing participants with the highest investigated dose of 3 x 106 cells/kg.

Overall response rate was 41.7% and median progression free survival was 7.2 months.

Jason Westin, MD, FACP, leader, DLBCL research team, MD Anderson Cancer Center, discussed results from the ZUMA-7 trial at ASCO 2022.

The phase 1/2 trial of VX880 remains on clinical hold in the US.

The findings suggest that less disadvantaged patients with high disease burden may have greater ability to advocate for CAR T-cell therapy.